AIR
Clinical safety rating
cautionComprehensive clinical and safety monograph for AIR (AIR).
AIR is not a recognized drug; no mechanism available.
| Metabolism | No metabolism data. |
| Excretion | Albuterol is primarily excreted renally as unchanged drug (approximately 60-70%) and as metabolites (sulfate conjugates via SULT1A3). Biliary/fecal elimination accounts for less than 10%. Total clearance is 0.53 L/h/kg. |
| Half-life | Terminal elimination half-life is 3.8-6.0 hours. Clinically, this supports dosing every 4-6 hours for bronchodilation; however, in acute exacerbations, more frequent dosing may be used due to shorter distribution half-life (~0.5 hours) and rapid offset of bronchoprotection. |
| Protein binding | Approximately 10% bound to plasma proteins (primarily albumin). Low binding minimizes drug interactions via displacement. |
| Volume of Distribution | Apparent volume of distribution (Vd) is 1.0-1.5 L/kg (total body water), indicating extensive distribution into tissues, including lung, heart, and skeletal muscle. This supports rapid onset and systemic effects at higher doses. |
| Bioavailability | Inhaled: 10-20% (via metered-dose inhaler with spacer; dependent on inhalation technique). Oral: 50% (first-pass metabolism in gut wall and liver by sulfotransferases and catechol-O-methyltransferase). IV: 100%. |
| Onset of Action | Inhaled: 5-15 minutes (immediate bronchodilation via beta-2 receptors). Oral: 30-60 minutes (peak effect at 2 hours). IV: 5-15 minutes. |
| Duration of Action | Inhaled: 3-6 hours (bronchodilation) with clinical note that protection against bronchoconstriction may wane before symptom return. Oral: 4-8 hours. Sustained-release oral formulations: up to 12 hours. Duration is dose-dependent and may be shorter in patients with airway hyperreactivity. |
| Molecular Weight | 200 |
| Brand Substitutes | Montina-L Tablet, Lecope-M Tablet, Monticope Tablet, Levocet M Tablet, Ronycold-M Tablet |
Not applicable. AIR is an acronym; if referring to a drug, please specify the generic name.
| Dosage form | GAS |
| Renal impairment | Not applicable. |
| Liver impairment | Not applicable. |
| Pediatric use | Not applicable. |
| Geriatric use | Not applicable. |
| 1st trimester | Contraindicated due to risk of fetal abnormalities; teratogenic effects reported in animal studies. |
| 2nd trimester | Avoid; associated with fetal growth restriction and oligohydramnios. |
| 3rd trimester | Avoid; risk of premature closure of ductus arteriosus and fetal renal impairment. |
Clinical note
Comprehensive clinical and safety monograph for AIR (AIR).
| Placental transfer | Crosses the placenta; achieves fetal concentrations approximately 50-100% of maternal levels. |
| Breastfeeding | Excreted into breast milk in low concentrations; may cause adverse effects in the infant such as irritability and feeding difficulties. Use only if potential benefit outweighs risk. |
| Lactation Rating | L3 - Moderately Safe |
| Teratogenic Risk | AIR is a bronchodilator combination (formoterol and budesonide). Budesonide, a corticosteroid, has low teratogenic risk; data from large cohort studies show no significant increase in congenital malformations. Formoterol, a beta-2 agonist, has limited human data but animal studies show no evidence of teratogenicity at therapeutic doses. Both agents are generally considered safe in pregnancy when benefits outweigh risks. First trimester: no known major teratogenic risk. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, or hypokalemia with high doses of formoterol; budesonide may slightly increase risk of low birth weight but no major malformations. |
| Fetal Monitoring | Monitor maternal respiratory status, fetal growth (ultrasound for growth restriction with prolonged high-dose corticosteroids), fetal heart rate (if high-dose beta-agonist used), and maternal blood glucose and potassium levels in late pregnancy if high doses of formoterol are used. |
| Fertility Effects | No known adverse effects on fertility in humans. High-dose corticosteroids may prolong estrous cycle in animals; no human data suggest significant impact. |
■ FDA Black Box Warning
No black box warning.
| Serious Effects |
Hypersensitivity to AIRThird trimester of pregnancyBreastfeeding in high-dose regimens
| Precautions | No warnings available. |
| Food/Dietary | No significant food interactions. Caffeine may increase stimulant effects; limit excessive consumption. Avoid foods that may trigger allergic reactions if patient has food allergies. |
| Clinical Pearls | AIR (albuterol) is a short-acting beta-2 agonist for acute bronchospasm. Monitor for tachycardia and hypokalemia. Use with caution in patients with cardiovascular disorders. For continuous nebulization, use high-dose protocol under medical supervision. |
| Patient Advice | Use only as needed for symptom relief; do not exceed prescribed frequency. · Rinse mouth after inhalation to prevent oral thrush. · Seek emergency care if symptoms worsen or if the inhaler provides less relief. · Shake inhaler well before each use and prime if new or unused for 2 weeks. · Avoid spraying in eyes; if contact occurs, flush with water. |
Loading safety data…